| Exagen is engaged in commercializing a portfolio of testing products under its AVISE® brand, several of which are based on its Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess the activation of the complement system, a biological pathway that is implicated across various autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE). Co.'s main testing product, AVISE® CTD, enables diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs), and other related diseases with overlapping symptoms. AVISE® CTD utilizes Co.'s CB-CAPs technology to enable the diagnosis SLE. We show 8 historical shares outstanding datapoints in our XGN shares outstanding history coverage, used to compute XGN market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing XGN market cap history over the course of time is important for investors
interested in comparing XGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of XGN versus a peer is one thing; comparing
XGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like XGN can fluctuate over the course of history.
With this page we aim to empower investors researching XGN by allowing them to research the XGN market cap history.